Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 24:13:1180366.
doi: 10.3389/fcimb.2023.1180366. eCollection 2023.

Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan

Ni Liu  1 , Min Liu  1   2 , Jun Yang  1   3 , Shuwei Dong  1 , Ming Yue  4 , Peng Huang  4 , Xueshan Xia  1   5 , A-Mei Zhang  1
Affiliations

Association of genetic polymorphisms in the C19orf66 gene and biochemical indices of HBV infected individuals in Yunnan

Ni Liu et al. Front Cell Infect Microbiol. .

Abstract

Introduction: Hepatitis B virus (HBV) infection causes serious liver diseases and is a healthy problem worldwide. Although vaccines are administered to infants after birth, there is no effective medicine for HBV infection. The interferon-stimulated genes (ISGs) are important factors in the host that can aid in restraining the virus, and the C19orf66 gene has a wide-antiviral spectrum.

Methods: In this study, three SNPs in the C19orf66 gene were sequenced and genotyped, and their potential function were predicted and further verified by dual-luciferase reporter assay.

Results: Although no significant difference of genotype and allele frequency was observed between HBV patients and the controls, the genotype and allele frequency showed significant difference between HBV patients with HBsAg-positive and HBV patients with HBsAg-negative or controls. Genotype AA (P= 0.009) and AT (P= 0.019) of rs77076061 showed higher and lower frequency in HBV patients with HBsAg-positive than in patients with HBsAg-negative, respectively. Genotype AG of rs1979262 played a risk role in HBV patients with HBsAg-positive (13.22%) than in patients with HBsAg-negative (7.53%, P= 0.036) or controls (8.48%, P= 0.033). The frequency of allele A of rs1979262 was higher in patients with HBsAg-positive (6.61%) than in patients with HBsAg-negative (3.77%, P= 0.042), while it was the opposite for the allele G. Moreover, the associations between genotypes of SNPs in the C19orf66 gene and the ALT, AST, and DBIL level were also identified. The functional assay suggested that the SNPs might influence the C19orf66 expression by changing the connection of transcriptional factors.

Conclusion: In summary, the association between genetic polymorphisms in the C19orf66 gene and HBV infection/biochemical indices of patients was firstly identified in Yunnan Province.

Keywords: HBV infection; biochemical indices; functional assay; genetic polymorphisms; the C19orf66 gene.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Dual-luciferase reporter assay. (A) the relative ratio of Firefly/Renilla for allele A and T of rs77076061; (B) the relative ratio of Firefly/Renilla for allele C and T of rs12611087; (C) the relative ratio of Firefly/Renilla for allele A and G of rs1979262. * means P< 0.05, ** means P<0.01, *** means P< 0.001.
See this image and copyright information in PMC

References

    1. Chen J., Chen H., Mai H., Lou S., Luo M., Xie H., et al. . (2022). A functional variant of CD40 modulates clearance of hepatitis b virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis. Hum. Mol. Genet 32 (8), 1334–1347. doi: 10.1093/hmg/ddac284 - DOI - PMC - PubMed
    1. Chen Y., Lu R., Zheng H., Xiao R., Feng J., Wang H., et al. . (2015). The NFKB1 polymorphism (rs4648068) is associated with the cell proliferation and motility in gastric cancer. BMC Gastroenterol. 15, 1521. doi: 10.1186/s12876-015-0243-0 - DOI - PMC - PubMed
    1. Inoue T., Tanaka Y. (2020). Novel biomarkers for the management of chronic hepatitis b. Clin. Mol. Hepatol. 26 (3), 261–279. doi: 10.3350/cmh.2020.0032 - DOI - PMC - PubMed
    1. Kinast V., Plociennikowska A., Anggakusuma, Bracht T., Todt D., Brown R. J. P., et al. . (2020). C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. J. Hepatol. 73 (3), 549–558. doi: 10.1016/j.jhep.2020.03.047 - DOI - PubMed
    1. King J. K., Yeh S. H., Lin M. W., Liu C. J., Lai M. Y., Kao J. H., et al. . (2002). Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis b patients: a pilot study. Hepatology 36 (6), 1416–1424. doi: 10.1053/jhep.2002.37198 - DOI - PubMed

Publication types

Substances